Newsletter Life Sciences
Check out the 3rd edition of the Life Sciences newsletter with the regulatory highlights in the health sector.
The main news came from the Brazilian Federal Court, which suspended the resolution of the Federal Pharmacy Council (CFF) that allowed pharmacists to prescribe over-the-counter medicines. The measure, challenged by the Federal Council of Medicine (CFM), reignited the debate about the limits of professional attributions and raised concerns about patient safety.
Anvisa resumed disclosure of medical device price data, strengthening market transparency, and launched Anvisalegis, an email push service for regulatory publications. It also presented RDC 954/2024, which simplifies drug registration processes, and published two new guides for biological products and radiopharmaceuticals.
Other relevant advances included the mandatory use of the WHODrug dictionary for the reporting of adverse events by companies, the disclosure of the active ingredients that will be evaluated in the Periodic Benefit-Risk Reports in 2025, and the opening of a public consultation to update the regulation of cannabis-based products. March was therefor a month of intense movement towards modernizing and improving the Brazilian health regulatory environment.
Download the material: